20.59
price down icon0.72%   -0.15
after-market After Hours: 20.62 0.03 +0.15%
loading
Dianthus Therapeutics Inc stock is traded at $20.59, with a volume of 190.85K. It is down -0.72% in the last 24 hours and down -11.78% over the past month. Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$20.74
Open:
$20.7
24h Volume:
190.85K
Relative Volume:
0.72
Market Cap:
$661.46M
Revenue:
$4.12M
Net Income/Loss:
$-56.68M
P/E Ratio:
-3.7147
EPS:
-5.5429
Net Cash Flow:
$-51.44M
1W Performance:
-5.98%
1M Performance:
-11.78%
6M Performance:
-26.73%
1Y Performance:
-22.13%
1-Day Range:
Value
$20.30
$21.58
1-Week Range:
Value
$20.00
$22.57
52-Week Range:
Value
$18.34
$33.77

Dianthus Therapeutics Inc Stock (DNTH) Company Profile

Name
Name
Dianthus Therapeutics Inc
Name
Phone
929-999-4055
Name
Address
7 TIMES SQUARE, NEW YORK
Name
Employee
78
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
DNTH's Discussions on Twitter

Compare DNTH with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
DNTH
Dianthus Therapeutics Inc
20.59 661.46M 4.12M -56.68M -51.44M -5.5429
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
512.52 131.61B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
672.36 73.51B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
619.97 37.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.44 32.81B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
266.26 28.62B 3.81B -644.79M -669.77M -6.24

Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-20-24 Initiated TD Cowen Buy
Oct-03-24 Initiated Oppenheimer Outperform
Jul-26-24 Initiated Robert W. Baird Outperform
Jun-27-24 Initiated Cantor Fitzgerald Overweight
May-16-24 Initiated H.C. Wainwright Buy
Feb-15-24 Initiated Stifel Buy
Dec-26-23 Initiated Jefferies Buy
Nov-22-23 Initiated Wedbush Outperform
Oct-30-23 Initiated Guggenheim Buy
Sep-28-23 Initiated Raymond James Outperform
Aug-25-22 Downgrade Goldman Buy → Neutral
Jan-06-22 Upgrade Goldman Neutral → Buy
Aug-20-21 Resumed Goldman Neutral
Aug-03-21 Downgrade JP Morgan Overweight → Neutral
Jul-22-21 Reiterated B. Riley Securities Buy
Jun-29-21 Initiated Cantor Fitzgerald Overweight
Jun-15-21 Initiated BTIG Research Buy
May-18-21 Initiated B. Riley Securities Buy
Jan-07-21 Initiated Mizuho Buy
Jun-08-20 Upgrade Goldman Neutral → Buy
Mar-25-19 Downgrade Goldman Buy → Neutral
Mar-15-19 Initiated Raymond James Outperform
View All

Dianthus Therapeutics Inc Stock (DNTH) Latest News

pulisher
12:33 PM

FY2025 Earnings Forecast for DNTH Issued By Lifesci Capital - MarketBeat

12:33 PM
pulisher
Mar 18, 2025

Wedbush Equities Analysts Reduce Earnings Estimates for DNTH - MarketBeat

Mar 18, 2025
pulisher
Mar 18, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 3.8%Here's Why - MarketBeat

Mar 18, 2025
pulisher
Mar 17, 2025

HC Wainwright Reaffirms "Buy" Rating for Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat

Mar 17, 2025
pulisher
Mar 17, 2025

FY2025 EPS Estimates for DNTH Raised by Cantor Fitzgerald - Defense World

Mar 17, 2025
pulisher
Mar 17, 2025

Q1 EPS Estimate for Dianthus Therapeutics Lifted by Analyst - MarketBeat

Mar 17, 2025
pulisher
Mar 17, 2025

HC Wainwright Issues Optimistic Outlook for DNTH Earnings - Defense World

Mar 17, 2025
pulisher
Mar 16, 2025

Dianthus Therapeutics' (DNTH) Outperform Rating Reiterated at Wedbush - MarketBeat

Mar 16, 2025
pulisher
Mar 16, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap DownWhat's Next? - MarketBeat

Mar 16, 2025
pulisher
Mar 16, 2025

Dianthus Therapeutics (DNTH) Projected to Post Quarterly Earnings on Thursday - MarketBeat

Mar 16, 2025
pulisher
Mar 15, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat

Mar 15, 2025
pulisher
Mar 15, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 5.5%Here's Why - MarketBeat

Mar 15, 2025
pulisher
Mar 15, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Issues Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat

Mar 15, 2025
pulisher
Mar 15, 2025

Research Analysts Set Expectations for DNTH Q1 Earnings - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

HC Wainwright Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

Guggenheim Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

Wedbush Reaffirms “Outperform” Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Dianthus Therapeutics' (DNTH) "Buy" Rating Reaffirmed at Guggenheim - MarketBeat

Mar 13, 2025
pulisher
Mar 13, 2025

We're Not Very Worried About Dianthus Therapeutics' (NASDAQ:DNTH) Cash Burn Rate - Yahoo Finance

Mar 13, 2025
pulisher
Mar 13, 2025

Dianthus Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Mar 13, 2025
pulisher
Mar 13, 2025

Dianthus Therapeutics (DNTH) to Release Quarterly Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Mar 13, 2025

Dianthus Therapeutics Reports 2024 Financial Results and Clinical Progress - TipRanks

Mar 13, 2025
pulisher
Mar 12, 2025

Stifel maintains Buy rating on Dianthus Therapeutics stock By Investing.com - Investing.com Canada

Mar 12, 2025
pulisher
Mar 12, 2025

Dianthus Therapeutics shares fall as Q4 results miss expectations By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Dianthus Therapeutics shares fall as Q4 results miss expectations - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Optimistic Buy Rating for Dianthus Therapeutics Driven by Promising DNTH103 Data and Pipeline Progress - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Dianthus Therapeutics: Strong Financials and Promising Clinical Trials Justify Buy Rating - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of “Buy” by Brokerages - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results - The Manila Times

Mar 11, 2025
pulisher
Mar 11, 2025

Dianthus Therapeutics, Inc. /DE/ SEC 10-K Report - TradingView

Mar 11, 2025
pulisher
Mar 11, 2025

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 - Bluefield Daily Telegraph

Mar 11, 2025
pulisher
Mar 11, 2025

Dianthus Therapeutics: Promising Growth Potential with Innovative DNTH103 and Strong Financial Position - TipRanks

Mar 11, 2025
pulisher
Mar 10, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 8.2%Still a Buy? - MarketBeat

Mar 10, 2025
pulisher
Mar 09, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year LowShould You Sell? - MarketBeat

Mar 09, 2025
pulisher
Mar 07, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Position Boosted by Rhumbline Advisers - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.3%Should You Sell? - MarketBeat

Mar 06, 2025
pulisher
Mar 05, 2025

John King named commercial head at Dianthus - BioCentury

Mar 05, 2025
pulisher
Mar 05, 2025

Dianthus Therapeutics appoints John King as CCO By Investing.com - Investing.com Canada

Mar 05, 2025
pulisher
Mar 05, 2025

Dianthus Therapeutics Appoints Sujay Kango to Board - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Dianthus Therapeutics announces board changes - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

Dianthus Therapeutics appoints John King as CCO - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

Dianthus Therapeutics announces board changes By Investing.com - Investing.com UK

Mar 05, 2025

Dianthus Therapeutics Inc Stock (DNTH) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$78.94
price up icon 2.53%
$318.85
price up icon 1.51%
$33.41
price up icon 0.00%
$20.11
price up icon 1.41%
$99.27
price up icon 0.31%
biotechnology ONC
$266.26
price up icon 1.87%
Cap:     |  Volume (24h):